| abstract |
The AGE-2 aptamer of the present invention binds to glyceraldehyde-derived advanced glycation end product (AGE-2) but does not bind to human serum albumin and consists of at least 35 bases, and the cytosine content in the bases is at least 35% or the guanine content in the base is at least 32%. Since the AGE-2 aptamer of the present invention can be used to detect AGE-2, it is a disease involving AGE-2 such as diabetic complications such as diabetic retinopathy, diabetic nephropathy, diabetic neuropathy and the like. It can be used as a detection / diagnostic agent and prophylactic / therapeutic agent for neurodegenerative diseases such as Alzheimer's disease, malignant tumor growth, metastasis, and invasion. |